

**S1 Table.** Overview of cancer patients' characteristics and outcomes by year

Variable	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
No. of patients	324	368	366	465	532	591	674	677	744	738
Age at admission (yr)	65.9±13.7	64.4±14.9	64.6±15.4	64.8±14.1	65.5±14.0	66.9±13.9	66.7±14.1	66.1±13.9	67.0±14.0	67.3±14.1
White race	193 (59.6)	268 (72.8)	265 (72.4)	348 (74.8)	418 (78.6)	456 (77.2)	530 (78.6)	553 (81.7)	569 (76.5)	558 (75.6)
DNR at admission	18 (6.0)	24 (6.8)	27 (7.8)	31 (7.0)	48 (9.3)	40 (7.0)	59 (10.6)	45 (10.5)	44 (10.6)	52 (12.7)
Use of vasopressors	98 (30.2)	113 (30.7)	123 (33.6)	140 (30.1)	150 (28.2)	157 (26.6)	177 (26.3)	167 (24.7)	193 (25.9)	171 (23.2)
Use of ventilation	151 (46.6)	183 (49.7)	171 (46.7)	238 (51.2)	238 (44.7)	252 (42.6)	264 (39.2)	299 (44.2)	315 (42.3)	269 (36.4)
Connective tissue malignancy	11 (4.3)	11 (3.7)	15 (5.5)	22 (5.9)	15 (3.5)	26 (5.4)	27 (4.9)	40 (7.2)	30 (5.1)	25 (4.3)
Gastrointestinal malignancy	70 (27.1)	83 (27.9)	68 (25.0)	105 (28.3)	121 (28.3)	129 (26.9)	166 (29.9)	142 (25.5)	172 (29.1)	158 (26.9)
Genitourinary malignancy	50 (19.4)	44 (14.8)	21 (7.7)	53 (14.3)	60 (14.1)	59 (12.3)	75 (13.5)	60 (10.8)	89 (15.0)	100 (17.0)
Oral malignancy	5 (1.9)	8 (2.7)	4 (1.5)	7 (1.9)	5 (1.2)	4 (0.8)	9 (1.6)	14 (2.5)	16 (2.7)	5 (0.9)
Respiratory malignancy	54 (20.9)	64 (21.5)	74 (27.2)	84 (22.6)	103 (24.1)	107 (22.3)	130 (23.4)	129 (23.2)	118 (19.9)	126 (21.4)
Other/ unclassified solid malignancy	68 (26.4)	87 (29.3)	90 (33.1)	100 (27.0)	123 (28.8)	155 (32.3)	148 (26.7)	171 (30.8)	167 (28.2)	174 (29.6)
Metastatic solid cancers	79 (24.4)	137 (37.2)	109 (29.8)	149 (32.0)	157 (29.5)	200 (33.8)	216 (32.0)	230 (34.0)	227 (30.5)	218 (29.5)
Leukemia	22 (31.9)	24 (32.4)	42 (44.2)	41 (41.8)	44 (40.0)	50 (43.1)	39 (31.0)	48 (36.4)	67 (40.6)	69 (42.1)
Lymphoma	36 (52.2)	36 (48.6)	43 (45.3)	44 (44.9)	46 (41.8)	44 (37.9)	65 (51.6)	64 (48.5)	76 (46.1)	75 (45.7)
Unclassified/other hematologic malignancies	11 (15.9)	14 (18.9)	10 (10.5)	13 (13.3)	20 (18.2)	22 (19.0)	22 (17.5)	20 (15.2)	22 (13.3)	20 (12.2)
Renal replacement therapy	15 (4.6)	17 (4.6)	7 (1.9)	21 (4.5)	24 (4.5)	22 (3.7)	36 (5.3)	27 (4.0)	33 (4.4)	40 (5.4)
Elixhauser Comorbidity Score	15.0±10.9	17.0±11.5	17.4±12.0	18.9±12.7	17.9±12.5	19.7±12.7	19.2±12.8	19.9±12.8	20.0±13.1	19.7±13.5
SOFA score	3.3±2.9	3.5±2.7	3.6±2.8	3.8±2.9	3.6±2.8	3.5±2.8	3.7±2.8	3.5±2.5	3.7±2.7	3.5±2.8
APACHE-III score	45.6±23.2	43.8±20.9	46.3±20.7	45.4±21.2	45.6±22.4	45.5±19.7	46.9±22.4	45.3±19.4	46.9±21.0	44.3±18.3
ICU length of stay (day)	5.1±8.3	5.1±5.7	5.3±6.6	4.8±6.6	4.8±6.7	4.1±4.6	4.1±5.5	4.0±4.2	4.2±5.6	3.6±4.0
Hospital length of stay (day)	11.5±10.6	11.0±10.2	12.7±11.9	11.1±9.4	11.8±10.9	10.9±9.7	10.5±9.1	10.6±11.8	10.8±10.3	9.8±8.4
28-Day mortality	108 (33.3)	113 (30.7)	109 (29.8)	157 (33.8)	150 (28.2)	167 (28.3)	175 (26.0)	154 (22.7)	196 (26.3)	174 (23.6)

1-Year Mortality 192 (59.3) 215 (58.4) 219 (59.8) 278 (59.8) 304 (57.1) 346 (58.5) 386 (57.3) 381 (56.3) 425 (57.1) 376 (50.9)

---

Values are presented as number (%) or mean±standard deviation. DNR, do not resuscitate; SOFA, Sequential Organ Failure Assessment Score; APACHE-III, Acute Physiologic Assessment and Chronic Health Evaluation Score; ICU, intensive care unit.